Fundraising Fox
Novasenta
Pittsburgh, US · Founded 2018 · Delaware corporation
Find your way into Novasenta
Sign up to see every warm intro you have to Novasenta
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Novasenta team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Novasenta is a biotechnology company that uses single-cell analysis of human tissue samples combined with computational biology to discover novel therapeutic targets and develop treatments for immune-mediated diseases and cancer.
Founders & leadership
Novasenta was founded in 2018 by Greg M. Delgoffe, Robert Ferris, and Dario A. A. Vignali.
GM
Greg M. DelgoffeCo-Founder & Director
RF
Robert FerrisCo-Founder & Scientific Advisor
DA
Dario A. A. VignaliCo-Founder
MK
Matthias KleinzNamed on SEC filing
MM
Mani MohindruNamed on SEC filing
Board
JC
Jeanne CunicelliBoard director
Reported raises · per SEC filings
Form D private placements$25M disclosed across 2 rounds · 2022–2023
▶$15MraisedFeb 2024 · 1 investors · BiotechnologyRule 506(b)
▶$15MraisedFeb 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David MooreDirector
- Greg DelgoffeDirector
- Jeanne CunicelliDirector
- Mani MohindruExecutive Officer, Director
- Matthias KleinzDirector
- Offering amount
- $30M
- Amount sold
- $15M
- First sale
- Dec 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedJul 2022 · 1 investors · BiotechnologyRule 506(b)
▶$10MraisedJul 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthias KleinzDirector
- Mani MohindruExecutive Officer, Director
- Jeanne CunicelliDirector
- Greg DelgoffeDirector
- Offering amount
- $20M
- Amount sold
- $10M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 4
GenentaGenenta Science is a clinical-stage biotechnology company developing Temferon, a hematopoietic stem cell-based gene therapy platform for treating cancer. The company is publicly traded on Nasdaq under the ticker GNTA.
ZentalisZentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
UPMCUPMC is a regional healthcare provider that invests in community health through charity care, free and subsidized health programs, and support for seniors, veterans, and food-insecure populations.
Enanta PharmaceuticalsEnanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need. Its work has contributed to hepatitis C virus combination therapies, and its pipeline includes programs in areas such as respiratory syncytial virus (RSV).
Companies working in the same space as Novasenta.
Frequently asked questions
- What does Novasenta do?
- Novasenta is a biotechnology company that uses single-cell analysis of human tissue samples combined with computational biology to discover novel therapeutic targets and develop treatments for immune-mediated diseases and cancer.
- Who founded Novasenta?
- Novasenta was founded by Greg M. Delgoffe, Robert Ferris, Dario A. A. Vignali in 2018.
- How much funding has Novasenta raised?
- Novasenta has disclosed $25M raised across 2 rounds.
- Where is Novasenta headquartered?
- Novasenta is headquartered in Pittsburgh, US.